10X Genomics, Inc.

10X Genomics, Inc. has recently revised its evaluation amid current market dynamics. The stock is priced at $25.24, reflecting a notable annual performance with a 214.32% return. Technical indicators present a mixed outlook, while the company has shown significant volatility over the past year.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a notable performance with a 14.29% gain over the past year. Despite this progress, the company remains unprofitable, with a negative return on equity and no dividends offered, highlighting ongoing financial challenges.

10X Genomics, Inc. has recently undergone an evaluation revision amid current market dynamics. The company’s stock is priced at $23.00, reflecting a notable annual performance with a 165.28% return. Technical indicators present a mixed outlook, highlighting the company's volatility and the need for continued performance monitoring.

10X Genomics, Inc. has shown strong market performance, with notable gains over the past month and year, significantly outperforming the S&P 500. The company boasts solid financial metrics, including a robust operating cash flow and a high level of institutional holdings, reflecting investor confidence.

10X Genomics, Inc. has achieved a new 52-week high of USD 23.60, significantly up from its low of USD 6.94. Despite a modest one-year performance of 3.79%, the company maintains a market capitalization of USD 2,132 million, reflecting its position in the competitive biotechnology sector.

10X Genomics, Inc. has seen a significant rise in its stock performance, reaching an intraday high. Over the past year, it has outperformed the S&P 500, despite recent short-term declines. The company enjoys strong institutional ownership and has achieved its highest operating cash flow, though it faces challenges with negative return on equity.

10X Genomics, Inc. faced a notable decline in its stock price, reaching an intraday low amid a challenging trading session. Despite a significant drop over the past week, the company has strong institutional support and a market capitalization of USD 2,412 million, with no dividend currently offered.

10X Genomics, Inc. has faced a significant stock decline today, reaching an intraday low. Despite recent challenges, the company has shown mixed performance metrics, with a notable annual return and strong institutional ownership. However, long-term performance over three and five years remains concerning.

10X Genomics, Inc. has recently experienced a stock price decline, reflecting its complex market dynamics. While the company has outperformed the S&P 500 over the past year, it has faced significant challenges in longer-term performance. Technical indicators present mixed signals, indicating varying market sentiments.

10X Genomics, Inc. has shown notable market activity, gaining 12.56% today and reaching an intraday high of USD 22.17. The company has achieved a 15.32% increase over the past week and an impressive 89.96% return over the last year, significantly outperforming the S&P 500.

10X Genomics, Inc. has recently revised its evaluation amid notable stock price fluctuations, currently at $22.13. The company has achieved a nearly 90% return over the past year, significantly outperforming the S&P 500. Technical indicators show mixed performance, with some bullish trends and neutral momentum signals.

10X Genomics, Inc. saw a notable stock price increase on November 7, 2025, amid a modest rise in the broader market. The company has shown strong weekly and monthly performance, despite a decline over the past year. High institutional ownership reflects investor confidence, while challenges remain with negative EBITDA.

10X Genomics, Inc. experienced a notable stock price increase on October 31, 2025, despite facing a challenging year with a significant decline. The company has high institutional ownership but struggles with negative financial metrics, indicating ongoing profitability issues amid a volatile market environment.

10X Genomics, Inc. has recently seen a stock price of $11.60, reflecting volatility over the past year with a high of $18.21 and a low of $6.78. The company has faced significant challenges, with a notable decline in stock performance compared to the S&P 500 over various timeframes.

10X Genomics, Inc. has faced significant stock price declines, with a year-to-date drop of 19.22% and a 41.5% decrease over the past year. Despite reporting strong operating cash flow and high institutional ownership, the company struggles with negative EBITDA and long-term underperformance compared to the S&P 500.

10X Genomics, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock price at $13.04. Over the past year, the company has experienced significant volatility, reflected in a return of -44.46%. Technical indicators show mixed signals, highlighting the need for careful performance monitoring.